

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY
Petitioner

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Patent Owner

IPR2018-01425
Patent No. 9,890,210

PETITIONER'S UPDATED EXHIBIT LIST AS OF SEPTEMBER 10, 2019

Further to 37 C.F.R. § 42.63(e), Petitioner Eli Lilly and Company hereby submits a current listing of Lilly Exhibits.

Exhibit	Description	Served Not Filed
Ex. 1001	U.S. Patent No. 9,890,210	
Ex. 1002	Reserved	
Ex. 1003	Reserved	
Ex. 1004	Reserved	
Ex. 1005	Reserved	
Ex. 1006	Reserved	
Ex. 1007	Reserved	
Ex. 1008	Reserved	
Ex. 1009	Reserved	
Ex. 1010	Declaration of Andrew Charles, M.D. (U.S. Patent No. 9,890,210)	
Ex. 1011	Declaration of Alain P. Vasserot (U.S. Patent No. 9,890,210)	
Ex. 1012	Reserved	
Ex. 1013	Reserved	
Ex. 1014	Reserved	
Ex. 1015	Reserved	
Ex. 1016	Reserved	

Exhibit	Description	Served Not Filed
Ex. 1017	Reserved	
Ex. 1018	Reserved	
Ex. 1019	Teva's U.S. Provisional Application No. 60/736,623	
Ex. 1020	Teva's PCT Application No. WO 2007/054809	
Ex. 1021	Tan et al., "Demonstration of the Neurotransmitter Role of Calcitonin Gene-Related Peptides (CGRP) by Immunoblockade with Anti-CGRP Monoclonal Antibodies," <i>Br. J. Pharmacol.</i> (1994) 111: 703-710	
Ex. 1022	Tan et al., "Calcitonin Gene-Related Peptide as an Endogenous Vasodilator: Immunoblockade Studies in vivo with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody and Its Fab' Fragment," <i>Clinical Sci.</i> (1995) 89: 565-573	
Ex. 1023	Queen et al., U.S. Patent No. 6,180,370	
Ex. 1024	Doods et al., "Pharmacological Profile of BIBN4096BS, the First Selective Small Molecule CGRP Antagonist," <i>Br. J. Pharmacol.</i> (2000) 129: 420-423	
Ex. 1025	Olesen et al., "Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine," <i>N. Engl. J. Med.</i> (2004) 350: 1104-1110	
Ex. 1026	Sveinsson, International Publication No. WO 2004/014351	
Ex. 1027	Salmon et al., U.S. Patent Application Publication No. US 2002/0162125	
Ex. 1028	De Lacharriere et al., U.S. Patent No. 6,344,438	

Exhibit	Description	Served Not Filed
Ex. 1029	Olesen et al., "S26 CGRP Antagonism as a New Therapeutic Principle in Acute Migraine," <i>Neuropeptides</i> (2004) 38: 110-131	
Ex. 1030	Arndt et al., "CGRP Antagonism — A Valid New Concept for the Treatment of Migraine Pain," <i>Neuropeptides</i> (2004) 38: 110-131	
Ex. 1031	Arulmani et al., "Calcitonin Gene-related Peptide and Its Role in Migraine Pathophysiology," <i>Eur. J. Pharmacol.</i> (2004) 143: 315-330	
Ex. 1031A	Arulmani et al., "Calcitonin Gene-related Peptide and Its Role in Migraine Pathophysiology," <i>Eur. J. Pharmacol.</i> (2004) 143: 315-330	X
Ex. 1032	Frobert et al., "A Sensitive Sandwich Enzyme Immunoassay for Calcitonin Gene-Related Peptide (CGRP): Characterization and Application," <i>Peptides</i> (1999) 20: 275-284	
Ex. 1032A	Frobert et al., "A Sensitive Sandwich Enzyme Immunoassay for Calcitonin Gene-Related Peptide (CGRP): Characterization and Application," <i>Peptides</i> (1999) 20: 275-284	X
Ex. 1033	Wong et al., "Monoclonal Antibody to Rat α -CGRP: Production, Characterization, and in vivo Immunoneutralization Activity," <i>Hybridoma</i> (1993) 12: 93-106	
Ex. 1033A	Wong et al., "Monoclonal Antibody to Rat α -CGRP: Production, Characterization, and in vivo Immunoneutralization Activity," <i>Hybridoma</i> (1993) 12: 93-106	X

Exhibit	Description	Served Not Filed
Ex. 1034	Rist et al., "From Micromolar to Nanomolar Affinity: A Systematic Approach to Identify the Binding Site of CGRP at the Human Calcitonin Gene-Related Peptide 1 Receptor," <i>J. Med. Chem.</i> (1998) 41: 117-123	
Ex. 1034A	Rist et al., "From Micromolar to Nanomolar Affinity: A Systematic Approach to Identify the Binding Site of CGRP at the Human Calcitonin Gene-Related Peptide 1 Receptor," <i>J. Med. Chem.</i> (1998) 41: 117-123	X
Ex. 1035	Edvinsson and Hargreaves, <i>The Headaches</i> 289-299 (3rd ed. 2006)	
Ex. 1035A	Edvinsson and Hargreaves, <i>The Headaches</i> 289-299 (3rd ed. 2006)	X
Ex. 1036	Reserved	
Ex. 1037	Reserved	
Ex. 1038	Mason et al., "Release of the Predicted Calcitonin Gene-Related Peptide from Cultured Rat Trigeminal Ganglion Cells," <i>Nature</i> (1984) 308: 653-655	
Ex. 1038A	Mason et al., "Release of the Predicted Calcitonin Gene-Related Peptide from Cultured Rat Trigeminal Ganglion Cells," <i>Nature</i> (1984) 308: 653-655	X
Ex. 1039	Brain et al., "Calcitonin Gene-Related Peptide is a Potent Vasodilator," <i>Nature</i> (1985) 313: 54-56	
Ex. 1039A	Brain et al., "Calcitonin Gene-Related Peptide is a Potent Vasodilator," <i>Nature</i> (1985) 313: 54-56	X
Ex. 1040	Arulmozhi et al., "Migraine: Current Concepts and Emerging Therapies," <i>Vascular Pharmacol.</i> (2005) 43: 176-187	

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.